CSWYY (China Shineway Pharmaceutical Group) 5-Year EBITDA Growth Rate: 12.70% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSWYY China Shineway Pharmaceutical Group Ltd CSWYY
86 GF Score
Price $19.25
GF Value $15.55
! 2 Warning Signs
View Full Analysis

What is China Shineway Pharmaceutical Group 5-Year EBITDA Growth Rate?

China Shineway Pharmaceutical Group CSWYY 86 5-Year EBITDA Growth Rate is 12.70% as of Dec. 2025. GuruFocus rates CSWYY with a GF Score™ of 86/100 and a GF Value™ of $15.55. The stock has 2 warning signs investors should review.

China Shineway Pharmaceutical Group's EBITDA per Share for the six months ended in Dec. 2025 was $1.86.

During the past 12 months, China Shineway Pharmaceutical Group's average EBITDA Per Share Growth Rate was 14.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 6.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.70% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Shineway Pharmaceutical Group was 42.30% per year. The lowest was -17.70% per year. And the median was 6.05% per year.

China Shineway Pharmaceutical Group  (OTCPK:CSWYY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

China Shineway Pharmaceutical Group 5-Year EBITDA Growth Rate Related Terms

CSWYY vs ZTS, UTHR: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Shineway Pharmaceutical Group 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where China Shineway Pharmaceutical Group's 5-Year EBITDA Growth Rate falls into.


CSWYY
86GF Score
China Shineway Pharmaceutical Group Ltd CSWYY
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Shineway Pharmaceutical Group 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 12.70% mean?
China Shineway Pharmaceutical Group (CSWYY) has a 5-Year EBITDA Growth Rate of 12.70% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for China Shineway Pharmaceutical Group and its competitors.
Is China Shineway Pharmaceutical Group's 5-Year EBITDA Growth Rate too high?
China Shineway Pharmaceutical Group's current 5-Year EBITDA Growth Rate is 12.70%. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's 5-Year EBITDA Growth Rate compare to ZTS and UTHR?
China Shineway Pharmaceutical Group's 5-Year EBITDA Growth Rate of 12.70% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for China Shineway Pharmaceutical Group and its competitors. China Shineway Pharmaceutical Group's current 5-Year EBITDA Growth Rate is 12.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current 5-Year EBITDA Growth Rate of 12.70%. The stock's GF Value™ is $15.55, compared to a current price of $19.25 — trading 23.8% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 12.70%. China Shineway Pharmaceutical Group's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current 5-Year EBITDA Growth Rate is 12.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?

Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued. The current stock price of $19.25 is trading 23.8% above its estimated GF Value™ of $15.55.

Key valuation signals for CSWYY:

  • 5-Year EBITDA Growth Rate: 12.70%
  • GF Value™: $15.55 vs. price of $19.25 (23.8% above fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Shineway Pharmaceutical Group Business Description

Other Exchanges 02877:Hong KongC1S:Germany
Address Luan Cheng, Hebei Province, Shijiazhuang, CHN
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
86GF Score

Get the complete analysis for CSWYY

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.25
Price
$15.55
GF Value